LOTTE Holdings, Co., Ltd. (Tokyo, Japan; CEO: Genichi Tamatsuka, hereinafter “LOTTE Holdings”) announces an investment in Alveus Therapeutics, Inc. (hereinafter “Alveus Therapeutics”), a rapidly ...
The companies have identified an initial set of genetic biomarkers to predict drug response and will validate the findings in ...
Biomed Industries, Inc. Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity and Cardiovascular ...
It's 'definitely not a measure of fatness,' and it doesn't accurately define what it means to be overweight. Body mass index isn't always the best predictor of health. In the age of weight-loss drugs, ...
Researchers found that the risk of type 2 diabetes varies among young adults. Those with high fasting glucose who qualified ...
A research team affiliated with UNIST has made a significant discovery explaining why liver cancers associated with obesity ...
With obesity rates hovering around one in three adults, looser pricing could make semaglutide standard of care ...
A Phase III trial of Rhythm Pharmaceuticals’ Imcivree (setmelanotide) failed to meet its primary endpoints in four rare, ...
Three new studies reveal surprising insights on GLP-1 weight loss drugs, opioid treatment in pregnancy, and the real science ...
Although the window for Rhythm Pharmaceuticals’ Imcivree to break out of the genetic obesity realm is quickly approaching ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results